At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09939 KINTOR PHARMA-B
Market Closed 11-20 16:08:27
1.310
-0.055
-4.03%
High1.325
Low1.270
Vol895.50K
Open1.325
D1 Closing1.365
Amplitude4.03%
Mkt Cap653.69M
Tradable Cap653.69M
Total Shares499.00M
T/O1.16M
T/O Rate0.18%
Tradable Shares499.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
GENFLEET-B (02595) Spends HK$2.1157 Million to Repurchase 120,000 Shares on November 20
Hong Kong Stock Movers | GENFLEET-B (02595) Gains Over 5% as First Patients in China and Overseas Dosed in GFH276 Pancreatic Cancer Combination Therapy Study
Genfleet-B (02595): Pan-RAS Inhibitor GFH276 Combination Therapy for Pancreatic Cancer Completes First Patient Dosing in China and Overseas, Phase II to Include Three First-Line Combination Regimens
Institutions: Chip structure rebalancing nearly complete, focus on AI applications, new energy, and pharma; gain exposure via CSI 300 ETF Huatai-PineBridge (510300)
TYK Medicines-B Jumps Over 9% in Early Trading as First Batch of Cardasha Nears Production Completion, Commercial Launch in China Expected by Late November
Kintor Pharmaceutical Ltd is an investment holding company primarily engaged in the research and development of innovative medicine products. The Company's products are dedicated to addressing disease areas that have not met clinical needs, and its pipeline mainly covers indications of dermatology (such as androgenetic alopecia, acne vulgaris) and indications of tumors. The Company has two core drugs in the dermatology field, KX-826 and GT20029. The Company's other disease areas include metastatic castration-resistant prostate cancer (mCRPC), liver cancer, idiopathic pulmonary fibrosis, malignant blood diseases and various solid tumors.